Inhalation Drug Product Development Services

Orally inhaled and nasal drug product (OINDP) development services including CMC support for registration (NDAs/ANDAs), formulation development, GMP testing, product characterisation, stability testing and clinical manufacturing services for small molecule and biologic OINDPs

Orally inhaled and nasal drug product development demands a rigorous approach to formulation, testing, stability and CMC requirements in order to optimize product efficacy, quality, safety and performance. 

With 30 years of experience in supporting our clients’ OINDP development, our experts provide formulation development, repurposing or reformulation, product characterisation studies, method development and validation, inhalation product analysis, device verification testing, in vitro bioequivalence testing, CMC support for NDAs/ANDAs and clinical manufacturing services. With the largest GMP ICH stability storage facility in Europe, we manage all aspects of stability including storage, long-term and accelerated stability across product's development from early preclinical to commercial batch stability. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory expectations.